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system for the preparation and propagation of
cell therapy-compliant human adipose stem cells
Mimmi Patrikoski1,2,3*, Miia Juntunen1,2,3, Shayne Boucher4, Andrew Campbell5, Mohan C Vemuri4,
Bettina Mannerström1,2,3 and Susanna Miettinen1,2,3Abstract
Introduction: Adipose tissue is an attractive and abundant source of multipotent stem cells. Human adipose
stem cells (ASCs) have shown to have therapeutic relevancy in diverse clinical applications. Nevertheless, expansion
of ASCs is often necessary before performing clinical studies. Standard in vitro cell-culture techniques use
animal-derived reagents that should be avoided in clinical use because of safety issues. Therefore, xeno- and
serum-free (XF/SF) reagents are highly desirable for enhancing the safety and quality of the transplanted ASCs.
Methods: In the current study, animal component-free isolation and cell-expansion protocols were developed for
ASCs. StemPro MSC SFM XF medium with either CELLstart™ CTS™ coating or Coating Matrix Kit were tested for their
ability to support XF/SF growth. Basic stem-cell characteristics such as immunophenotype (CD3, CD11a, CD14,
CD19, CD34, CD45RO, CD54, CD73, CD80, CD86, CD90, CD105, HLA-DR), proliferation, and differentiation potential
were assessed in XF/SF conditions and compared with human serum (HS) or traditionally used fetal bovine serum
(FBS) cultures.
Results: ASCs cultured in XF/SF conditions had significantly higher proliferation rates compared with HS/FBS
cultures. Characteristic immunophenotypes of ASCs were maintained in every condition; however, cells expanded in
XF/SF conditions showed significantly lower expression of CD54 (intercellular adhesion molecule 1, ICAM-1) at low
passage number. Further, multilineage differentiation potential of ASCs was maintained in every culture condition.
Conclusions: Our findings demonstrated that the novel XF/SF conditions maintained the basic stem cell features of
ASCs and the animal-free workflow followed in this study has great potential in clinical cell therapies.
Keywords: Adipose stem cells, Xeno-free, Serum-free, Human serum, Fetal bovine serum, Multipotentiality,
Proliferation rate, Immunophenotype, Flow cytometry, Cell therapyIntroduction
Human adipose tissue is an abundant source of mul-
tipotent stem cells known as adipose stem cells (ASCs),
and they have the ability to differentiate toward various
mesenchymal cell types, including bone, cartilage, and
fat cells [1,2]. Since Zuk et al. [3] described this unlim-
ited source of multipotent cells, growing interest exists
toward the clinical applicability of ASCs. The therapeutic* Correspondence: mimmi.patrikoski@uta.fi
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Tampere, Tampere, Finland
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reproduction in any medium, provided the orrelevance of the cells has been noticed and, in fact, the
number of clinical cell therapies using ASCs has been
steadily increassing [4-6]. Therefore, increased focus oc-
curs on the safety, efficacy, reproducibility, and quality of
the cells used in clinical treatments.
ASCs and bone marrow-derived stem cells (BMSCs)
alike are mesenchymal stem cells (MSCs) that are de-
fined as plastic-adherent cells with the potential to
differentiate toward bone-, fat-, and cartilage-like cells.
Furthermore, for their characterization, it is required
that the cells express (≥95%) certain markers on the cell
surface (CD105, CD73, and CD90) and lack the expres-
sion of hematopoietic antigens (≤2%) [7].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ulatory properties such as regulation of T-cell functions,
antiinflammatory cytokine expression, and prolongation
of allotransplant survival [8,9]. Thus, ASCs have been
shown to suppress allogeneic lymphocytes both in vitro
and in vivo [9,10]. In addition, ASCs lack the expression
of MHC class II molecules as well as T- and B-cell co-
stimulatory molecules CD80, CD86, and CD40 on their
cell surfaces [11]. Because of these characteristics, ASCs
are strong candidates for the treatment of immunolo-
gic disorders such as severe graft-versus-host disease or
Crohn disease. Furthermore, because of their low im-
munogenicity, they may be used in allogeneic stem cell
therapies, such as in the treatment of bone defects. High
proliferation rate and good differentiation potential are
important from the clinical point of view, and therefore,
off-the-shelf cell products could be used to achieve ef-
fective treatments by using allogeneic cells with func-
tional stem cell characteristics.
Cell-based therapies typically require large numbers of
cells, and expansion of ASCs is often necessary before
clinical use. Traditionally, fetal bovine serum (FBS) has
been used in ASC cultures because of its ability to sup-
port cell growth and attachment by providing nutrients
and attachment factors for the cells. However, in clinical
cell therapies, the use of animal-derived reagents should
be avoided, and the risks and benefits carefully asses-
sed because of safety concerns [12,13]. Alternatives for
FBS have been studied, such as allogeneic human serum
(alloHS) or autologous HS (autoHS) [14], as well as
platelet-derived supplements [15,16]. Nevertheless, limi-
tations connected to the use of serum or its components
exist, such as lot-to-lot variation with serum-supple-
mented media performance, affecting differentiation po-
tential and proliferation rate [17]. In addition, limited
availability of autoHS can make long-term cultures of
ASCs impractical. It is noteworthy that no standardized,
fully defined xeno- and serum-free (XF/SF) cultivation
protocols are available. However, the safety and the qual-
ity of transplanted ASCs would be significantly enhanced
by replacing undefined and animal-derived components
with defined XF/SF reagents.
The aim of the current study was to develop safe and
efficient XF/SF culture conditions for ASCs and to show
that ASCs cultured under these novel XF/SF conditions
maintained their stem-cell characteristics, including the
multilineage differentiation potential, immunophenotype,
and proliferation capacity. The cell isolation and expan-
sion was carried out in parallel in three different culture
conditions, under fully defined completely XF/SF condi-
tions, as well as in medium containing HS or FBS to
compare the cell characteristics between these condi-
tions. This study demonstrates the development of a
fully defined animal origin-free culture system for thepropagation and expansion of clinically relevant human
adipose stem cells for the purpose of cell therapy.
Methods
Isolation and culture of ASCs
The study was conducted in accordance with the ethics
committee of the Pirkanmaa Hospital District, Tampere,
Finland (R03058). ASCs were isolated from adipose tis-
sue samples obtained with written informed consent
from four female donors (age, 36 ± 9 years) undergoing
elective surgical procedures in the Department of Plastic
Surgery, Tampere University Hospital, Tampere, Finland.
To assess how serum supplementation of the culture
media affects the cell characteristics, ASCs were isolated
under three different culturing conditions: in medium
containing FBS, HS, or in XF/SF culture conditions. FBS-
and HS-containing media were used as reference media
for testing two different XF/SF culture conditions: (a) XF/
SF media with CELLStart coating, and (b) XF/SF media
with novel coating-free supplement, referred to hereafter
as Coating Matrix Kit.
Isolation of adipose stem cells (ASCs) from adipose
tissue samples was carried out by using a mechanical
and enzymatic method, as described previously [1,18,19].
In brief, the adipose tissue was minced manually into
small fragments and digested with collagenase NB 6
GMP Grade (SERVA Electrophoresis GmbH, Heidelberg,
Germany) in a water bath at 37°C under shaking condi-
tions. The digested tissue was centrifuged and filtered in
sequential steps through a 100-μm pore-size filter to
separate the ASCs from the surrounding tissue. The first
passage after the seeding of cells on cell-culture plastics,
after dissociation of fat tissue, was designated passage 0.
Cells were expanded in T75 flasks and passaged after
reaching 80% confluency.
For HS and FBS conditions, Dulbecco modified Eagle
medium (DMEM)/F-12 1:1 (Life Technologies, Gibco,
Carlsbad, CA, USA) was supplemented with 1% l-analyl
-l-glutamine (GlutaMAX I; Life Technologies, Gibco), 1%
antibiotics (p/s; 100 U/ml penicillin, 0.1 mg/ml strepto-
mycin; Lonza, BioWittaker, Verviers, Belgium) and serum
from either 10% FBS (Life Technologies, Gibco) or 10%
alloHS (Human Serum Type AB; Lonza, BioWhittaker,
Walkersville, MD, USA) was used. ASCs isolated and ex-
panded in FBS medium were detached by using 1% trypsin
(Lonza, Biowhittaker, Verviers, Belgium), and ASCs isolated
in HS medium were detached by using TrypLE Select (Life
Technologies, Gibco) for XF detachment of cells.
For SF/XF conditions, one third of the cells were
isolated under SF/XF conditions, and seeded on
carboxyl-coated flasks (PureCoatCarboxyl T75; BD
Biosciences, Franklin Lakes, NJ, USA) and expanded
in STEMPROW MSC SFM (Life Technologies, Gibco)
supplemented with 1% l-analyl-l-glutamine, 0.3%
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plement. Amine-coated flasks (PureCoat™ Amine T75;
BD Biosciences) were initially tested for their suitability
for XF/SF, but the coating was not supportive enough for
cell attachment, and instead of amine flasks, the carboxyl-
coated flasks were selected for further studies.
From passage 1 onward, additional supplements were
used in XF/SF conditions to support cell attachment and
growth in normal Nunclon flasks. Thus, XF/SF cells were
expanded in STEMPRO MSC medium supplemented with
either Coating Matrix Kit (XF/SF CM) (Life Technologies,
Gibco) or CELLstart™ CTS™ coating (XF/SF CS) (Life Tech-
nologies, Gibco), according to manufacturer's instructions.
ASCs isolated and expanded in SF/XF medium were de-
tached by using TrypLE Select for XF detachment of cells.
All culture-media formulations are presented in Table 1,
and a flow chart of the isolation as well as performed ana-
lyses in different culture conditions are illustrated in
Figure 1. All the analyses were performed separately with
four donor cell lines isolated in FBS, HS, and XF/SF
conditions.
Proliferation assay
The cell viability and proliferation activity were assessed
in the different culture conditions (FBS, HS, and SF/XF)
by using the PreMix WST-1 Cell Proliferation Assay
System (Takara Bio Inc., Shiga, Japan). ASCs (n = four
donor cell samples/analysis, passages 2 and 5) were
seeded on 48-well plates at a density of 2,500 cells/cm2,
and the proliferation was assessed at 1, 4, 7, and 11 days.
In brief, at each time point, the cell-culture medium
was removed, and DPBS (Dulbecco Phosphate-Buffered
Saline, Lonza, BioWhittaker, Verviers, Belgium) and
PreMix WST-1 were added 10:1. The 48-well plate
was incubated for 4 hours at 37°C, and the relative cell-
proliferation activity was measured in a microplate
reader (Victor 1429 Multilabel Counter) at 450 nm.
The population doubling was determined by using the
formula x = log2(NH)/(N1), where N1 is the absorbance
value at day 1, and NH is the absorbance value at ob-
served time point 4, 7, or 11, as described previously
[20]. To calculate the cumulative population doubling,Table 1 Culture-media formulation overview
Acronym Basal media Serum Coating/co
HS DMEM/F-12 Human serum None
FBS DMEM/F-12 Fetal bovine serum None
XF/SF CM StemPro MSC SFM None Coating Ma
XF/SF CS StemPro MSC SFM None CELLstart™
MSC, mesenchymal stem cell; p/s, penicillin/streptomycin; SFM, serum-free mediumthe population doubling was determined in each passage
and compared with the population doubling of earlier
passages.Flow-cytometric analysis of immunophenotype
ASCs expanded in SF/XF, HS, and FBS (n = 4, passages
2 and 5) media were analyzed with flow cytometry
(FACSAria; BD Biosciences, Erembodegem, Belgium) to
determine whether different culturing conditions have
an effect on the immunophenotype of the cells. Mo-
noclonal antibodies (MAbs) against CD11a–allophycoc-
yanin (APC), CD80–phycoerythrin (PE), CD86–PE,
CD105–PE (R&D Systems Inc., Minneapolis, MN, USA),
CD-3 (PE), CD14–phycoerythrin-cyanine (PECy7),
CD19-PECy7, CD45RO-APC, CD54-fluorescein isothio-
cyanate (FITC), CD73-PE, CD90-APC (BD Biosciences),
and CD34-APC, HLADR-PE (Immunotools GmbH,
Friesoythe, Germany) were used. Analysis was perfor-
med on 10,000 cells per sample, and unstained cell
samples were used to compensate for the background
autofluorescence levels.Differentiation analyses
The trilineage differentiation potential of ASCs (n = 4,
passages 2 to 5) toward osteogenic, adipogenic and chon-
drogenic cells was evaluated in XF/SF conditions versus
HS and traditionally used FBS-supplemented medium.
Differentiation capacity of ASCs was evaluated after 14
days of differentiation in either adipogenic, osteogenic, or
chondrogenic medium versus cells cultured in control
medium. Media for differentiation and control cultures
were changed 3 times per week during the differentiation
studies. The culture-media formulations used for diffe-
rentiation assays are shown in Table 2. In a subsequent
smaller-scale study, ASCs were primed for 3 days un-
der FBS- or HS-supplemented media before differenti-
ating under osteogenic or adipogenic condition. For
this, commercial serum-based StemPro Adipogenesis
and Osteogenesis differentiation kits (Life Technologies,
Gibco) were used during the 14-day induction for XF/SF
cells.ating-free supplements Supplementation
1% GlutaMAX, 1% p/s
1% GlutaMAX, 1% p/s
trix Kit StemProW MSC SFM XenoFree supplement,
1% GlutaMAX, 0.3% p/s
coating StemPro MSC SFM XenoFree supplement,
1% GlutaMAX, 0.3% p/s
.
Figure 1 Work flow of the isolation and performed analyses of ASCs under different culture conditions. XF/SF isolation of ASCs was
carried out by using carboxyl-coated flasks, and onward from passage 1, two different XF/SF conditions were tested in basic Nunclon flasks;
Coating Matrix Kit, and CELLstart™ coating. Cell-proliferation rate, differentiation potential, and immunophenotype were analyzed in four different
culture conditions at passages 2 and 5.
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For alkaline phosphatase (ALP) staining, cells were seeded
on 12-well plates at a density of 2.5 × 103 cells/cm2.
The differentiation degree after 14 days of osteogenic
induction was determined by the level of ALP
activity by using a leukocyte ALP kit (Sigma-Aldrich, St.
Louis, MO, USA), as described previously [21]. In brief,
cell cultures were washed twice with DPBS and fixed with
4% paraformaldehyde (PFA) or citrate-buffered formalde-
hyde-acetone solution. Subsequently, cells were rinsed
with deionized water, and ALP staining solution was
added and incubated for 15 minutes. After rinsing the
cells with deionized water, color formation was analyzed
microscopically.
Oil Red-O staining
For adipogenic differentiation, ASCs were seeded on 12-
well plates at a density of 2.0 × 104 cells/cm2. After 14
days of adipogenic induction culture, differentiation was
confirmed by Oil Red-O staining, indicating the forma-
tion of intracellular lipid accumulation, as described
earlier [2]. In brief, the cells were washed 3 times in
DPBS and fixed with 4% PFA. Subsequently, cells were
rinsed with deionized water and pretreated with 60% iso-
propanol after the additions of the 0.5% Oil Red-O stain-
ing solution in 60% isopropanol (Sigma-Aldrich). After
15-minute incubation in RT, the cells were rinsed with
deionized water, and adipocytes were identified with mi-
croscopy as cells with red-stained lipid vesicles. In a later
study, the cells were directly fixed and stained with 0.5%Oil Red-O staining solution with 60% isopropanol and
then rinsed with distilled water before conducting mi-
croscopic assessment of adipocyte generation.
Alcian blue staining
The chondrogenic differentiation potential was assessed
with a micromass culture method, as described previ-
ously [3,19,22]. In brief, 8 × 104 cells were seeded on a
24-well culture plate in a 10-μl volume and were allowed
to adhere for 3 hours before the addition of chon-
drogenic induction medium. After 14 days of chondro-
genic induction, differentiation was confirmed by using
the Alcian blue staining method, as described earlier
[23]. In brief, ASC pellets were rinsed with DPBS and
fixed with 4% PFA. Subsequently, cells were rinsed twice
with deionized water and stored in 70% ethanol. Pellets
were dehydrated, embedded in paraffin, and sectioned
at 5-mm thickness. The sections were rehydrated and
stained with Alcian blue (pH 1.0) to detect sulfated gly-
cosaminoglycans (GAGs) by using Nuclear Fast Red
solution (Biocare Medical, Concord, MA, USA) as a
counterstain.
Real-time quantitative PCR
Total RNA was isolated by using the NucleoSpin RNA II
kit (Macherey-Nagel, Düren, Germany) according to
manufacturer’s instructions. The RNA samples were re-
verse transcribed to first-strand cDNA by using the
High-Capacity cDNA Reverse Transcriptase Kit (Applied
Biosystems, Foster City, CA, USA). The mRNA levels of
Table 2 Culture media formulations used for differentiation assays
Medium Basal
media
Serum Coating/coating-free
supplements
Supplementation
Adipogenic (FBS) DMEM/F-12 10% Fetal
bovine serum
None 1% GlutaMAX, 1% p/s, 33 μM biotin (Sigma), 1 μM
dexamethasone (Sigma), 100 nM insulin (Life Technologies),
17 μM pantothenate (Fluka, Buchs, Switzerland), 250 μM
isobutylmethylxanthine (IBMX; Sigma) for 48-hour induction
after cell seeding
Osteogenic (FBS) DMEM/F-12 10% Fetal
bovine serum
None 1% GlutaMAX, 1% p/s, 150 μM L-ascorbic acid 2-phosphate
(Sigma), 10 mM β-glycerophosphate (Sigma), 10 nM
dexamethasone (Sigma)
Chondrogenic (FBS/HS) DMEM/F-12 None None 1% GlutaMAX, 0.3% p/s, 10 mg/ml human serum albumin
(Sigma), 8 μg/ml holo-transferrin human (Sigma), 5 ng/ml
sodium selenite (Sigma), 10 μg/ml insulin (Life Technologies),
1 μg/ml linoleic acid (Sigma), 50 μM L-ascorbic acid
2-phosphate (Sigma), 55 μM sodium pyruvate
(Life Technologies), 23 μM L-proline (Sigma), 10 ng/ml
TGF-β (Sigma)
Adipogenic (HS) DMEM/F-12 10% Human
serum
None 1% GlutaMAX, 1% p/s, 33 μM biotin, 1 μM dexamethasone,
100 nM insulin, 17 μM pantothenate, 250 μM IBMX for
48-hour induction after cell seeding
Osteogenic (HS) DMEM/F-12 10% Human
serum
None 1% GlutaMAX, 1% p/s, 150 μM L-ascorbic acid 2-phosphate,
10 mM β-glycerophosphate, 10 nM dexamethasone
Adipogenic (XF/SF CS) StemPro MSC none CELLstart™ coating StemPro MSC SFM XenoFree supplement, 1% GlutaMAX,
0.3% p/s, 33 μM biotin, 1 μM dexamethasone, 100 nM insulin,
17 μM pantothenate, 250 μM IBMX for 48-hour induction after
cell seeding
SFM
Osteogenic (XF/SF CS) StemPro MSC none CELLstart™ coating StemPro MSC SFM XenoFree supplement, 1% GlutaMAX,
0.3% p/s, 150 μM L-ascorbic acid 2-phosphate, 10 mM
β-glycerophosphate, 10 nM dexamethasoneSFM
Chondrogenic
(XF/SF CS and XF/SF CM)
StemPro MSC None None 1% GlutaMAX, 0.3% p/s, 10 mg/ml human serum albumin,
8 μg/ml holo-transferrin human, 5 ng/ml sodium selenite,
10 μg/ml insulin, 1 μg/ml linoleic acid, 50 μM L-ascorbic
acid 2-phosphate, 55 μM sodium pyruvate, 23 μM L-proline,
10 ng/ml TGF-β
SFM
Adipogenic (XF/SF CM) StemPro MSC None Coating Matrix Kit StemPro MSC SFM XenoFree supplement, 1% GlutaMAX,
0.3% p/s, 33 μM biotin, 1 μM dexamethasone, 100 nM insulin,
17 μM pantothenate, 250 μM IBMX for 48-hour induction after
cell seeding
SFM
Osteogenic (XF/SF CM) StemPro MSC None Coating Matrix Kit StemPro MSC SFM XenoFree supplement, 1% GlutaMAX,
0.3% p/s, 150 μM L-ascorbic acid 2-phosphate, 10 mM
beta-glycerophosphate, 10 nM dexamethasoneSFM
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zed by the qRT–PCR method as described previously
[23]. In brief, the real-time detection of PCR product
was monitored by using the SYBR Green dye (Applied
Biosystems, Warrington, UK). The housekeeping gene,
the ribosomal phosphoprotein P0 (RPLP0), was used as
an internal control, and the relative expression level for
each gene was calculated according to a previously de-
scribed mathematical model [24]. The expression of
adipogenesis-associated genes, peroxisome proliferator-
activated receptor γ (PPARγ), and adipocyte Protein 2
(aP2) was analyzed as well as osteogenesis-associated
genes such as distal-less homeobox transcription factor
5 (DLX5), ALP, and runt-related transcription factor
2 (RUNX2). Sequences and accession numbers of allprimers (Oligomer Oy, Helsinki, Finland) are displayed
in Table 3. The reactions were conducted and monitored
with ABI Prism 7000 Sequence Detection System (Applied
Biosystems, Warrington, UK).
Statistical analyses
One-way ANOVA with Bonferroni post hoc test was
used to analyze the effect of different culture conditions
on cell-proliferation rate, cell surface-marker expression,
and differentiation potential by using IBM SPSS software
version 19 (IBM SPSS Statistics 19, USA). Differences in
proliferation rate between different culture conditions
were analyzed separately at each time point. The sta-
tistical analyses were performed at the significance level
P < 0.05, and data are presented as mean ± SD.
Table 3 Primer sequences of marker genes determined
Name Primer direction Sequences Product size (bp)
hRPLP01 Frw 50-AAT CTC CAG GGG CAC CAT T-30 70
Rev 50-CGC TGG CTC CCA CTT TGT-30
haP22 Frw 50-GGTGGTGGAATGCGTCATG-30 71
Rev 50-CAACGTCCCTTGGCTTATGC-30
hPPARG3 Frw 50-CAGTGTGAATTACAGCAAACC −30 100
Rev 50-ACAGTGTATCAGTGAAGGAAT-30
hRUNX24 Frw 50-CCCGTGGCCTTCAAGGT-30 76
Rev 50-CGTTACCCGCCATGACAGTA-30
hDLX55 Frw 50-ACCATCCGTCTCAGGAATCG-30 75
Rev 50-CCCCCGTAGGGCTGTAGTAGT-30
hALP6 Frw 50-ATGTCATCATGTTCCTGGGAGAT-30 79
Rev 50-TGGTGGAGCTGACCCTTGAG-30
1Ribosomal protein, large, P0, (Acc. No: NM_001002); 2fatty acid-binding protein 4, (Acc. No: NM_001442); 3peroxisome proliferator-activated receptor gamma (Acc.
No: NM_015869), 4runt-related transcription factor 2 (Acc. No: NM_004348); 4distal-less homeobox transcription factor 5 (Acc. No: NM_005221); 5alkaline
phosphatase (Acc. No: NM_000478).
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XF/SF isolation of ASCs was the most critical step of the
cell culture
The isolation of ASCs was conducted in three different
culture conditions, in completely XF/SF conditions by
using carboxyl-coated flasks (PureCoat™, BD), as well as
in HS- and FBS-supplemented medium by using normal
Nunclon™ cell-culture flasks. Carboxyl coating was used
during the passage 0 after isolation in XF/SF conditions
because Nunclon™ cell-culture flasks were unable to pro-
vide sufficient initial cell adhesion for ASCs in XF/SF
medium. Still, after the first passaging, ASCs were able
to grow in normal Nunclon™ flasks in XF/SF medium in
the presence of Coating Matrix kit or CELLstart™ coa-
ting. The adhesion of ASCs after isolation in XF/SF
medium was a critical step of XF/SF culture, and the
XF/SF isolation was not successful with all the cell lines;
cells from six donors were isolated, but only four donor
cell lines were able to adhere and stay viable under XF/
SF conditions. Thus, the isolation efficiency in XF/SF
conditions was donor dependent. Nevertheless, if the
cells were initially able to adhere, cell proliferation in
XF/SF medium was efficient in further passages, and the
cell-population doubling was notably faster than that in
FBS/HS-containing medium (Figure 2). Subsequently, all
experiments were carried out with four donor cell lines
isolated in HS, FBS, and XF/SF conditions.
Cumulative population doubling of ASCs expanded under
XF/SF conditions versus medium containing HS or FBS
The cumulative population doubling of ASCs in XF/SF
medium versus serum-containing medium was analyzed
with WST-1 assay at time points 1, 4, 7, and 11 days in
two passages, 2 and 5. A statistically significant increasein population doubling was seen in cells grown in XF/SF
conditions compared with serum containing medium in
passage 2 at 4-, 7-, and 11-day time points (Figure 2).
Furthermore, a statistically significant difference was
seen in passage 5 at 7- and 11-day time points between
cells grown in XF/SF CM medium and FBS-containing
medium (Figure 2).
Differences in population doublings between passages
2 and 5 were also statistically significant. In HS-sup-
plemented medium; population doubling in passage 5
was significantly increased as compared with passage 2
at 4-, 7-, and 11-day time points, and in FBS medium, a
statistically significant increase was seen in passage 5 at
days 4 and 11 time points (Figure 2). Of note in passage
5, the population doubling in HS medium was higher
than in FBS-containing medium at 11 days, whereas in
passage 2, it was vice versa.
Morphology of ASCs expanded under XF/SF conditions
versus HS- or FBS-containing medium
The morphologic differences between cells cultured in
different conditions were consistent with the cell charac-
teristics seen during the proliferation experiments. The
adhesion of the cells grown in XF/SF medium was rela-
tively weak during the isolation, which was also reflected
in the morphology of ASCs in XF/SF conditions. Cells
grown in the presence of serum adopted wide spindle-
shaped and almost cuboidal morphology, whereas XF/SF
cells were smaller, more spindle-shaped, and more fibro-
blast like (Figure 3). The morphologic differences sug-
gest that spindle-shaped cells may not be as strongly
attached as cells grown in serum-containing medium.
In addition to light microscopy, cell populations were
examined by flow cytometry, especially the uniformity of
Figure 2 WST-1 proliferation assay. Cumulative population
doubling was analyzed in different culture conditions, in FBS- and
HS-containing medium, as well as in XF/SF medium with Coating
Matrix Kit and with CELLstart™ coating at time points 1, 4, 7, and 11
day in two passages 2 (A) and 5 (B). The data in the diagrams are
presented as mean ± SD. Significantly higher cumulative population
doubling was observed in XF/SF conditions compared with HS/FBS
cultures in passage 2 at 4-, 7-, and 11-day time points. Furthermore,
statistically significant difference in population doubling were seen
in passage 5 at 7- and 11-day time points between cells grown in
XF/SF CM medium and FBS-containing medium.
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panded in XF/SF medium displayed a more homoge-
neous population, seen as a uniform cluster with less
debris when compared with cells expanded in serum-
containing medium (Figure 3).
Immunophenotype of ASCs expanded under XF/SF
conditions versus HS- or FBS-containing medium
Cell-surface marker expression of ASCs was analyzed
with flow cytometry to compare the expression profile of
cells expanded in XF/SF conditions against cells ex-
panded in HS- or FBS-containing medium at passages 2
and 5 (Figure 4). In general, the characteristic immun-
ophenotype of ASCs was maintained in every culturecondition, with some minor differences observed bet-
ween XF/SF conditions and serum-containing media, as
well as in the expression of specific markers between
passages 2 and 5.
ASCs showed positive expression (>90%) for the mar-
kers CD73 (Ecto 5’ nucleotidase), CD90 (Thy-1) and
CD105 (Endoglin) in all of the studied culture conditions
in both passages (Figure 4), except the slightly lower
expression of CD73 in FBS medium in P2 and CD105
in HS medium in P5. In contrast, ASCs lacked the
expression (<2%) of CD11a (Integrin α-L), CD14 (LPS-
Receptor), CD19 (B4), CD80 (B7-1), CD86 (B7-2), and
HLA-DR (major histocompatibility class II receptor) in
every culture condition with a few exceptions. Low ex-
pression (>2% to <7%) was observed for cells grown in
XF/SF CM condition at P2 (CD19, CD86), and in XF/SF
CS condition at P2 (CD19, CD80, CD86).
Moderate expression (>7% to <41%) was observed for
the hematopoietic progenitor and endothelial cell mar-
ker CD34, except for the low expression in FBS and HS
cultures at P5. ASCs lacked the expression of leukocyte
common antigen CD45 in FBS and HS cultures, and low
expression was observed in XF/SF conditions. The lar-
gest variation between different culture conditions was
seen in the expression of CD54, which showed signifi-
cantly lower expression in cells expanded under XF/SF
conditions compared with cells expanded in serum-
containing medium at P2. Furthermore, statistically sig-
nificant differences were seen between HS medium and
XF/SF conditions at passage 5. Generally, ASCs cultured
in FBS or HS medium showed moderate expression of
CD54 (intercellular adhesion molecule 1, ICAM1),
whereas low expression was observed for cells cultured
in XF/SF conditions. In addition, whereas the expression
of CD34 and CD54 was decreased from passage 2 to
passage 5, no statistical differences were observed be-
tween passages.Multipotentiality of ASCs expanded under XF/SF
conditions versus HS- or FBS-containing medium
To test the multilineage differentiation potential of ASCs
expanded under XF/SF conditions versus HS or FBS
medium, the differentiation capacity toward the adipo-
genic, osteogenic, and chondrogenic lineages was ana-
lyzed. After the 14 days of differentiation induction, the
differentiation degree was examined by specific staining
methods and by the analysis of gene expression.Adipogenic differentiation
In the adipogenic-induction cultures, oil droplets were
visible by light microscopy in cells expanded in HS- or
FBScontaining medium. In XF/SF induction culture, dif-
ferentiation was clearly initiated but did not progress
Figure 3 Cell morphology. (A) Morphologic images of cells cultured in different conditions: FBS, HS, XF/SF CM, and XF/SF CS at time
point 4 days in passage 2. The morphology of ASCs grown in XF/SF medium is more spindle-shaped and smaller than in cells grown under
serum-containing medium (FBS, HS). Scale bar, 100 μm. (B) Flow-cytometric analysis confirms the morphologic characteristics observed with light
microscopy. In XF/SF culture conditions (CM and CS), the cell cloud in the forward and side scatter is more uniform and contains less debris than
does a cloud of cells grown in FBS or HS medium, suggesting a more homogeneous population.
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in Oil Red-O staining (Figure 5).
Nevertheless, a trend of higher expression of the gene
PPARγ, the central transcriptional regulator of adipo-
genesis, was noted in XF/SF conditions as compared
with serum-containing medium, but no significant dif-
ferences were seen because of high standard deviation
(Figure 6A). Further, the expression of aP2 (fatty acid-
binding protein) (Figure 6B) was consistent with the
results of Oil Red-O staining (Figure 5). The most in-
tense differentiation was seen in HS medium, which wasdemonstrated by large oil droplets in Oil Red-O staining
and by a significant increase in the expression of aP2
gene (Figure 6B) in ASCs cultured in HS-supplemented
induction medium compared with HS control medium
and the cells in all the other induction media in passage
2. Although the serum-containing medium and espe-
cially HS medium appeared to be the best condition for
adipogenic differentiation, cells cultured under XF/SF
conditions showed signs of early differentiation.
Because the induction response of XF/SF cells to adi-
pogenic differentiation appeared to be attenuated under
Figure 4 Surface-marker expression of undifferentiated ASCs. Immunophenotype of cells expanded in four different culture conditions; FBS,
HS, XF/SF CM, and XF/SF CS was investigated in passages 2 and 5. The data in the diagrams are presented as mean ± SD. Cells expanded under
XF/SF conditions showed significantly lower expression of CD54 (ICAM-1) compared with cells expanded in serum containing medium in passage 2.
Furthermore, statistically significant differences in the expression of CD54 were seen between HS medium and XF/SF conditions in
passage 5. Characteristic immunophenotypes of ASCs were maintained in every culture conditions with minor differences.
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ded more nutrient-rich media to promote efficient adipo-
genesis. Cryopreserved ASCs cultured in FBS-containing
media (passage 1), XF/SF CS (passage 2), and XF/SF CM
(passage 2) were thawed, recovered, and grown in their
own media. After reaching near confluency, the ASCs
were harvested and plated into both FBS-containing or
HS-containing media and let grow for 3 days. Then the
medium was replaced with adipogenic induction media in
either FBS- or HS-containing condition and cultured for
14 days. As predicted, differentiation was more efficient
when primed with HS- or FBS-containing medium, but
HS media clearly displayed increased differentiation than
did FBS media (Figure 7). No noticeable differences were
noted between XF/SF CS and XF/SF CM cells when in-
duced with either FBS- or HS-based adipogenic media.
Osteogenic differentiation
In the osteogenic induction cultures, cells expanded in
HS- or FBS-containing medium showed slightly enhancedcapacity to undergo osteogenic differentiation than did
the cells expanded under XF/SF conditions, based on the
ALP staining (Figure 5). However, the proliferation rate of
ASCs grown in XF/SF medium was increased compared
with serum-containing medium and, as a result, the wells
became confluent, and cells started to detach. Therefore,
the weak ALP staining in XF/SF conditions may indi-
cate attachment difficulties of the cells in confluent
wells, although the osteogenic differentiation is ongoing
(Figure 5).
In addition to ALP staining, the osteogenic differenti-
ation was evaluated by the expression of osteogenesis-
specific genes. In contrast to ALP staining results, the
expression of Runx2 was increased in XF/SF conditions
as compared with serum-containing medium, and a sta-
tistically significant increase was seen between XF/SF
CM and FBS/HS induction media in passage 5 (Figure 6C).
Further, the response of DLX5 (Figure 6E) to the osteo-
genic induction was stronger in XF/SF cultured cells when
compared with FBS/HS conditions, and a statistically
Figure 5 Multilineage differentiation potential of ASCs. Differentiation potential of ASCs cultured in four different conditions; FBS, HS, XF/SF
medium with Coating Matrix Kit, or CELLstart coating was investigated toward adipogenic, osteogenic, and chondrogenic cells. Oil Red-O staining
indicates the formation of intracellular lipid in cells going through adipogenic differentiation (scale bar, 100 μm); ALP staining reveals the alkaline
phosphatase activity in osteogenic-differentiation cultures (scale bar, 300 μm), and Alcian blue staining recognizes the glycosaminoglycans of the
cells going through chondrogenic differentiation (scale bar, 100 μm). Adipogenesis and osteogenesis was more effective in serum-containing
media, whereas clearly the most intense chondrogenesis was seen in XF/SF cultures.
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cultured in XF/SF CM induction media when compared
with FBS/HS induction conditions, as well as XF/SF CM
control. Also, the alkaline phosphatase staining result was
verified at gene-expression level, where a trend of in-
creased expression was observed in every differentiation
culture condition when compared with control samples
(Figure 6D). Although the expression of alkaline phospha-
tase (ALP) was increased after induction, no significant
differences were seen because of high standard deviation.
To determine whether ALP staining could be en-
hanced, XF/SF cells were also tested with a serum-based
medium to see whether more-efficient osteogenesis
could be induced. Cryopreserved ASCs cultured under
FBS-containing media (passage 1), XF/SF CS (passage 2),
and XF/SF CM (passage 2) were thawed, recovered, and
grown in their own media. After reaching near confluency,the ASCs were harvested and plated into both FBS- and
HS-containing media and let grown for 3 days. After 3
days, the media were replaced with osteogenic induction
medium in either FBS- or HS-containing condition
and cultured for 14 days. Differentiation was more ef-
ficient when primed with HS- or FBS-containing medium
(Figure 7). No noticeable differences were noted between
XF/SF CS and XF/SF CM cells when induced with either
FBS- or HS-based osteogenic media.
Chondrogenic differentiation
Chondrogenic differentiation was more intense in XF/SF
conditions compared with serum containing medium,
shown by the Alcian blue staining of proteoglycans after
the micromass culture in chondrogenic induction me-
dium (Figure 5). The size of the pellet was also larger
in XF/SF conditions versus HS or FBS cultures. These
Figure 6 Gene-expression analysis. Differentiation-specific gene-expression analysis was performed after 14 days of differentiation induction,
versus control medium, in different culture conditions: FBS, HS, XF/SF medium with Coating Matrix Kit, and with CELLstart coating in passages 2
and 5. The expression of PPARγ gene (A) and aP2 gene (B) demonstrate adipogenesis after 14 days of adipogenic induction. Respectively, the
expression of Runx2 (C) ALP (D), and DLX5 (E) genes indicate osteogenic differentiation after 14 days of osteogenic induction. The expression of
ALP and DLX5 are presented in passage 5. A significant increase in the expression of aP2 was observed in HS-supplemented induction medium
compared with HS control medium, and the cells in all the other induction media in passage 2. Further, the expression of Runx2 was significantly
increased in XF/SF CM induction medium as compared with FBS/HS inductions in passage 5. Moreover, the response of DLX5 to the osteogenic
induction was significantly stronger in XF/SF CM-cultured cells when compared with FBS/HS conditions, as well as XF/SF CM control in passage 5.
AD, adipogenic differentiation; OD, osteogenic differentiation. The data in the diagrams are presented as mean ± SD.
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age differentiation since the formation of proteoglycans,
central components of cartilage tissue, is enhanced in
XF/SF cultures.
Discussion
Today, clinical cell therapies using ASCs are in progress,
and several clinical trials are ongoing [5] and require
more-reliable, reproducible, and safe methods for in vitro
expansion of the cells. Therefore, the transition from FBS-
or HS-medium supplementation to defined XF/SF culture
conditions would be one of the most important steps for-
ward in considering the suitability of ASCs for clinical use.
By removing all the animal-derived components as well as
the undefined serum from the cell-culture workflow,
the safety of the patient receiving cell transplant can
be improved.
Traditionally, ASC culture medium has been sup-
plemented with FBS, which is not a preferred option in
clinical therapies because of xenogeneic components
with critical safety issues [12,25]. Consequently, differentkinds of alternatives for FBS have been studied consider-
ing the clinical use of ASCs. Trivedi and colleagues [26]
replaced FBS with 20% human albumin during the ASC
expansion for clinical use to treat diabetes, whereas
Tzouvelekis and colleagues [27] used autologous plate-
let-rich plasma for the cell expansion to treat patients
with pulmonary fibrosis. AutoHS is currently used for
the expansion of ASC by our group for the reconstruc-
tion of bone defects in the craniomaxillofacial area
[4,28]. However, as mentioned earlier, limitations are as-
sociated with the use of autoHS or serum derivatives,
such as lot-to-lot variability [17], limited availability, and
undefined composition, and therefore, the use of XF/SF
medium would be the preferred option.
Studies have been performed on ASCs/BMSCs study-
ing the defined XF- or SF-culture conditions; Dromard
and colleagues [29] demonstrated that ASCs can be
expanded as floating spheres in defined SF-culture sys-
tems supplemented with 2% human plasma and specific
growth factors. Further, Santos et al. [30] investigated
a microcarrier-based bioreactor system for the XF/SF
Figure 7 Adipogenic and osteogenic differentiation potential of
ASCs after serum priming. Follow-up study on the differentiation
of ASCs performed in five different conditions: (1) FBS, (2) XF/SF CS
primed initially in FBS, (3) XF/SF CS primed initially in HS, (4) XF/SF
CM primed initially in FBS, and (5) XF/SF CM primed initially in HS.
Oil Red-O staining indicates the formation of intracellular lipid in
cells going through adipogenic differentiation (scale bar, 100 μm);
ALP staining reveals the alkaline phosphatase activity in osteogenic
differentiation cultures (scale bar, 100 μm). Inset images are the
paired undifferentiated negative controls. Differentiation toward
adipogenic and osteogenic cells was more efficient when primed
with HS- or FBS-containing medium.
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of human platelet lysate (PL) for FBS substitution has
been investigated by several groups. Schallmoser and
colleagues [15] introduced a standard protocol for plate-
let preparation for animal protein-free cultures of ASCs,
and Naajikens et al. [31] showed that PL-cultured ASCs
had a similar differentiation capacity and increased pro-
liferation rate when compared with FBS cultures. Blande
et al. [32], in contrast, showed that ASC populationdoubling time in PL cultures was significantly lower than
that in FBS cultures, but the immunophenotype was
similar, and both cultures retained the differentiation po-
tential of the cells.
Still, a better-defined culture environment is needed, and
to our knowledge, this study is the first report describing
ASC isolation and expansion in completely XF/SF condi-
tions maintaining the basic stem cell characteristics
of ASCs. In the past, XF or SF expansion of mesen-
chymal stem cells has been reported, but the cell
isolation and early expansion and differentiation stud-
ies were carried out in serum-containing medium
[19,30,33-35]. In this study, we isolated the cells with-
out serum exposure in XF/SF conditions by using BD
PureCoat carboxyl flasks. Onward from passage 1, the
cells were able to grow on basic Nunclon Δ surface vessels
in XF/SF conditions when either CELLstart CTS coating
or XF/SF CM was used. Considering the future clinical
applications, it is an advance that the cells are isolated and
expanded in fully XF/SF culture conditions instead of
using serum supplementation at any point of the culture.
If the patient is exposed to undefined components under
in vitro expansion, an increased risk occurs for cross-
contaminations and immune reactions in a patient receiv-
ing the cell transplant. Nevertheless, patient safety is still
the most important aspect considering clinical use of
ASCs.
In addition to safety, it is advantageous for in vitro ex-
pansion of cells to be performed in a shorter time scale.
Our studies on the cell-proliferation rate were consistent
with the results of earlier studies of mesenchymal stem
cell cultures under XF or SF conditions [19,33,34] in
which the higher proliferation rate of XF- or SF-cultured
cells compared with FBS cultures was demonstrated. In
our study, the cumulative population doubling in XF/SF
medium was superior when compared with both FBS
and HS conditions. Efficient expansion of ASCs in XF/SF
conditions is crucial for clinical sustainability where a
large cell number is required in a minimum time scale.
Cell surface-marker expression profile of ASCs was
largely similar between cells grown under different cul-
ture conditions, except the significant difference in the
expression of CD54 (ICAM-1), which is a marker of
endothelial cells and cells of the immune system. To our
knowledge, CD54 expression of ASCs has not been stud-
ied earlier in XF/SF conditions. The lower expression of
CD54 may suggest that a more homogeneous cell popu-
lation is achieved through more-selective isolation and
expansion protocols compared with cells isolated in the
presence of serum. In addition, weaker cell adhesion
under XF/SF conditions was observed, which may reflect
on lower expression of the adhesion molecule ICAM1
(CD54). This aspect of XF/SF cultures and the possible
selective effect on cell population has to be investigated
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is used.
Some variations were also seen in the expression of
CD11a (integrand am), CD14 (lip polysaccharide re-
ceptor), CD19 (leukotriene B4 receptor), and CD86
(costimulatory molecule for T-cell activation) on cells
grown in XF/SF conditions versus serum-containing
medium. All of these markers are known to interact
with immune-related cells, and therefore, the culture
conditions may affect the immunogenicity of ASCs.
The minimal criterion for the immunophenotype of
MSCs described by Dominici et al. [7] was defined for
cells cultured under standard condition in a medium
with FBS supplementation. However, our current results
with XF/SF cells demonstrate that the cell surface-mar-
ker profile applies to ASCs cultured under XF/SF condi-
tions as well. The hematopoietic progenitor cell marker
CD34 was moderately expressed in both XF/SF and
serum-supplemented conditions in contrast to earlier
described criteria. However, similar results for CD34 ex-
pression have been reported by others [36,37], and the
variable interpretations could be explained by differences
cell-culturing and -passaging protocols. In the current
study, the expression of CD34 and CD54 was higher in
passage 2, but the expression level was decreased in later
passages, indicating a more homogeneous population.
The chondrogenic differentiation capacity of ASCs
cultured under XF/SF conditions was strong compared
with cells cultured in serum-containing medium based
on the Alcian blue staining. Similar findings have been
shown by Chase et al. [31], in which a robust chondro-
genesis in SF-culture conditions was seen when com-
pared with serum-containing medium. In our study, the
Alcian blue staining of proteoglycans was intense in cells
expanded under XF/SF conditions, and also the pellet
size after micromass-culture was larger compared with
serum-containing medium, which was in agreement with
Chase’s results. This result promises potential use of
ASCs in chondrogenic applications, but further research
is needed to investigate the chondrogenic-differentiation
potential of ASCs in XF/SF conditions.
Moreover, the differentiation potential toward os-
teogenic and adipogenic cells was investigated in XF/SF
conditions. Unlike in previous studies [28,31,32], osteo-
genesis and adipogenesis was induced in totally XF/SF
differentiation media, and serum was substituted by XF/
SF supplement of the STEMPRO MSC SFM kit. When
ASCs were cultured under XF/SF conditions, they sho-
wed moderate differentiation potential toward osteo-
genic and adipogenic cells, as demonstrated by ALP and
Oil Red-O staining, as the differentiation was not as ef-
ficient as seen in serum-containing medium. By optimiz-
ing the differentiation protocols for each condition, the
efficiency of osteogenic and adipogenic differentiationcan be enhanced. Furthermore, the reduced differenti-
ation potential may be due to decreased cell adhesion
for cells undergoing differentiation under XF/SF condi-
tions. The weak cell-attachment hypothesis was suppor-
ted by altered morphology and cell detachment during
the proliferation studies, as well as decreased enzymatic
digestion time. Another explanation is that ASCs need a
more nutrient-rich media to promote robust differenti-
ation. The follow-up differentiation studies with FBS- or
HS-based media strongly indicate that nutrients play a
key role in efficient differentiation. These findings are
consistent with previous studies in which the importance
of cell adhesion and nutrients during the cell differenti-
ation has been shown [38,39].
In addition, the responses seem to be donor specific,
and possibly, some cell lines respond better to the os-
teogenic induction, whereas others respond better to
adipogenic induction. Thus, variation in the responses
exists, and different stages of differentiation are evident,
as shown by the high standard deviations of gene ex-
pressions. Also, the mRNA expression and enzymatic ac-
tivity may not be in line because the regulation occur on
posttranscriptional and translational levels, and finally,
on the level of formation of an active enzyme. The cells
cultured in different conditions may also be at different
stages of their differentiation process, thus not express-
ing the same markers simultaneously. Still, the activity
increase in gene-expression level shows commitment to
osteogenic or adipogenic pathway, depending on donor
cell line and culture condition.
Nevertheless, although at an early stage, differentiation
occurred in XF/SF medium, showing that the cells have
the capacity for trilineage differentiation, as shown by
Oil Red-O, ALP, and Alcian blue staining. Chase et al.
[33] demonstrated that BMSCs expanded in SF condi-
tions and differentiated in serum containing induction
medium retained their ability to differentiate into adipo-
cytes, chondrocytes, and osteoblasts. In addition, Yang
et al. [34] published similar results on the differentiation
potential of ASCs expanded in a hypoxic XF environ-
ment. The cells expanded in XF medium had equal mul-
tilineage differentiation capacity, as compared with cells
expanded in traditional serum-containing medium when
serum induction was used during the differentiation.
Taking these previous results into account, the efficiency
of differentiation could easily be improved by serum in-
duction during the culture in differentiation medium.
However, the aim of this study was to remove all the
undefined components from the cell-culture workflow,
and therefore, serum induction is not a preferred op-
tion for use during differentiation. Conversely, autoHS
supplementation may be used in clinical treatments for
differentiation induction, and the cells would still be ex-
panded in defined XF/SF conditions before differentiation.
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differentiated state, and the cell differentiation then occurs
in vivo, as has been performed by our group [4,28].
Additionally, growth factors and biomaterials can be
used to support cell differentiation in XF/SF conditions.
Cordonnier and co-workers [40] showed that growth-
factor induction is especially effective for cells cultured
in low serum. In their study, the effect of bone morp-
hogenetic proteins (BMPs) -2, -4, and −7 on osteogenic
differentiation of BMSCs was evaluated in low (2%) and
higher (10%) FBS-supplemented cultures, leading to a
conclusion that BMP-4 induction in low-serum cultured
cells was the most effective osteogenic inducer. Similarly,
the osteogenic differentiation potential of XF/SF cultured
ASCs could be enhanced by growth-factor induction. Fur-
thermore, the differentiation capacity of XF/SF-cultured
ASCs can be enhanced by inductive biomaterials, such as
osteopromoting bioactive glass [41] or β-tricalcium phos-
phate [42], or alternatively, chondrogenesis-inductive ma-
terials such as 3-D woven polycaprolactone scaffolds [43].
Conclusions
Effective and safe in vitro methods to isolate and expand
ASCs are critical for the positive development of cell-
therapy applications. Our current results demonstrate
that the novel XF/SF culture conditions maintains the
stem cell characteristics of ASCs. The cells grown in
different culture conditions displayed the characteristic
immunophenotype of ASCs with minor differences. Im-
portantly, the proliferation rate of ASCs was significantly
increased in XF/SF conditions, compared with HS- and
FBS-containing medium. Furthermore, the chondrogenic
differentiation potential was intense in XF/SF conditions,
whereas adipogenic and osteogenic differentiation were
comparable to the FBS condition after serum priming.
These novel XF/SF culture conditions have great po-
tential for clinical use, but additional preclinical safety
and efficacy studies will be needed and standardized be-
fore using in clinical treatments. Off-the-shelf cell prod-
ucts will require effective XF/SF conditions in which the
basic stem-cell characteristics of ASCs are maintained,
the proliferation rate is high, and the cells retain their
functionality. Naturally, a substantial number of safety-
assessment studies would have to be done before allo-
geneic ASCs can be used in clinical cell treatments. The
development of efficient and safe XF/SF-culture condi-
tions is one step closer to that goal.
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